Staszewski S - Search Results

1

Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy.

Cozzi-Lepri A, Ruiz L, Loveday C, Phillips AN, Clotet B, Reiss P, Ledergerber B, Holkmann C, Staszewski S, Lundgren JD; EuroSIDA Study Group. Cozzi-Lepri A, et al. Among authors: staszewski s. Antivir Ther. 2005;10(7):791-802. Antivir Ther. 2005. PMID: 16312176

2

Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts.

Mocroft A, Staszewski S, Weber R, Gatell J, Rockstroh J, Gasiorowski J, Panos G, Monforte Ad, Rakhmanova A, Phillips AN, Lundgren JD; EuroSIDA study group. Mocroft A, et al. Among authors: staszewski s. Antivir Ther. 2007;12(3):325-33. Antivir Ther. 2007. PMID: 17591022 Clinical Trial.

3

Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.

Bannister WP, Ruiz L, Cozzi-Lepri A, Mocroft A, Kirk O, Staszewski S, Loveday C, Karlsson A, Monforte Ad, Clotet B, Lundgren JD; EuroSIDA study group. Bannister WP, et al. Among authors: staszewski s. AIDS. 2008 Jan 30;22(3):367-76. doi: 10.1097/QAD.0b013e3282f3cc35. AIDS. 2008. PMID: 18195563

4

Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.

Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M, Phillips A, Staszewski S. Geretti AM, et al. Among authors: staszewski s. Antivir Ther. 2008;13(7):927-36. Antivir Ther. 2008. PMID: 19043927

5

The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors.

Fox ZV, Geretti AM, Kjaer J, Dragsted UB, Phillips AN, Gerstoft J, Staszewski S, Clotet B, von Wyl V, Lundgren JD. Fox ZV, et al. Among authors: staszewski s. AIDS. 2007 Oct 1;21(15):2033-42. doi: 10.1097/QAD.0b013e32825a69e4. AIDS. 2007. PMID: 17885293 Clinical Trial.

6

The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study.

Smith CJ, Olsen CH, Mocroft A, Viard JP, Staszewski S, Panos G, Staub T, Blaxhult A, Vetter N, Lundgren JD. Smith CJ, et al. Among authors: staszewski s. AIDS. 2008 Jan 2;22(1):47-56. doi: 10.1097/QAD.0b013e3282f03094. AIDS. 2008. PMID: 18090391

7

Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study.

Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group; Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Karafoulidou A, Miro JM, Lundgren J, Chene G, Egger M. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, et al. Antivir Ther. 2009;14(8):1065-74. doi: 10.3851/IMP1462. Antivir Ther. 2009. PMID: 20032536 Free PMC article.

8

Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression.

Phillips AN, Staszewski S, Lampe F, Youle MS, Klauke S, Bickel M, Sabin CA, Doerr HW, Johnson MA, Loveday C, Miller V; Royal Free Centre for HIV Medicine; Goethe Universität Clinic Cohort. Phillips AN, et al. Among authors: staszewski s. J Infect Dis. 2002 Oct 15;186(8):1086-91. doi: 10.1086/343801. Epub 2002 Sep 30. J Infect Dis. 2002. PMID: 12355358 Free article.

9

Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002.

Lampe FC, Gatell JM, Staszewski S, Johnson MA, Pradier C, Gill MJ, de Lazzari E, Dauer B, Youle M, Fontas E, Krentz HB, Phillips AN. Lampe FC, et al. Among authors: staszewski s. Arch Intern Med. 2006 Mar 13;166(5):521-8. doi: 10.1001/archinte.166.5.521. Arch Intern Med. 2006. PMID: 16534038

10

Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2.

ESPRIT Research Group; Fox Z, Antunes F, Davey R, Gazzard B, Klimas N, Labriola A, Losso M, Neaton JD, Phillips AN, Ruxrungtham K, Staszewski S, Weiss L, Lundgren JD. ESPRIT Research Group, et al. Among authors: staszewski s. HIV Med. 2007 Mar;8(2):112-23. doi: 10.1111/j.1468-1293.2007.00440.x. HIV Med. 2007. PMID: 17352768 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

251 results

Search Page

Filters